Challenges for Drug Repurposing in Covid-19
The corona virus disease (COVID-19) contagion has affected an estimated 16 million persons and caused 0.6 million deaths worldwide by September 2020. The contagion has led to a rush to repurpose existing drugs, although the elementary substantiation base is of variable quality. The enriching knowledge of the virology and clinical presentation of COVID-19 is leading to a broadening pool of implicit pharmacological targets. The intention is to describe executive and pharmacological aspects of medicine repurposing and to identify medicines proposed for repurposing in COVID-19 hung on registered clinical trials, bandying the substantiation to support their use in the treatment of this distemper. The challenges of the correct interpretation of breathing pre-clinical/ clinical substantiation as well as the generation of new substantiation concerning medicine repurposing in COVID-19 will also be agitated.
- SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.
- Functional Fine-Tuning of Metabolic Pathways by the Endocannabinoid System-Implications for Health and Disease.
- Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)
- Drug Repurposing in the COVID-19 Era